222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details


臨床試験数 : 310 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

  
21 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05772871
(ClinicalTrials.gov)
March 30, 202324/2/2023The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in ChildrenCompare the Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule Versus Combined With Levamisole for Primary Nephrotic Syndrome in Children: A Prospective, Multi-center, Randomized, Double-blind, Non-inferiority StudyNephrotic Syndrome in ChildrenDrug: Huaiqihuang granule;Drug: Prednisone;Drug: Levamisole placebo;Drug: Levamisole;Drug: Huaiqihuang Granule placeboJianhua ZhouLinkDoc Technology (Beijing) Co. Ltd.Not yet recruiting18 Months18 YearsAll402Phase 4NULL
2NCT04745728
(ClinicalTrials.gov)
April 14, 20214/2/2021Different Immunosuppressive Treatment in iMNDifferent Immunosuppressive Treatment in Idiopathic Membranous Nephropathy: a Prospective CohortIdiopathic Membranous NephropathyDrug: Prednisone;Drug: Cyclophosphamide;Drug: RituximabPeking Union Medical College HospitalNULLRecruiting18 Years80 YearsAll200Phase 3China
3ChiCTR2100041655
2020-12-302021-01-01Effect of thymosin 1 on recurrent minor nephrotic syndrome in adultsA prospective, randomized controlled trial of oral prednisone combined with thymosin 1 in recurrent adult patients with minimal lesions nephrotic syndrome Minimal change nephrotic syndromeOral prednisone:oral prednisone;Oral prednisone combined with thymosin 1 group:Thymosin 1 was injected;Affiliated Hospital of Guangdong Medical UniversityNULLRecruiting1870BothOral prednisone:27;Oral prednisone combined with thymosin 1 group:27;China
4NCT03970577
(ClinicalTrials.gov)
July 29, 202015/4/2019RItuximab From the FIRst Episode of Idiopathic Nephrotic SyndromeRituximab From the First Episode of Minimal Change Nephrotic Syndrome for Preventing Relapse Risk in Adult Patients: a Multicenter Randomized Controlled TrialMinimal Change Nephrotic Syndrome (MCNS)Drug: Rituximab;Drug: PrednisoneAssistance Publique - Hôpitaux de ParisNULLRecruiting18 YearsN/AAll148Phase 2France
5NCT04424862
(ClinicalTrials.gov)
June 9, 20207/6/2020Multitarget Therapy for Idiopathic Membranous NephropathyMultitarget Therapy for Idiopathic Membranous NephropathyEfficacyDrug: Prednisone, ciclosporin and mycophenolate mofetil;Drug: Ponticelli RegimenBeijing Friendship HospitalNULLCompleted18 Years70 YearsAll82Phase 4China
6EUCTR2018-003437-15-FR
(EUCTR)
03/04/201927/02/2019Rituximab from the FIRst Episode of Idiopathic Nephrotic SyndromeRituximab from the FIRst Episode of Idiopathic Nephrotic Syndrome - RIFIREINS Minimal Change Nephrotic Syndrome (MCNS)
MedDRA version: 20.0;Level: LLT;Classification code 10029168;Term: Nephrotic syndrome with lesion of minimal change glomerulonephritis;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: MabThera
Product Name: MabThera
INN or Proposed INN: RITUXIMAB
INN or Proposed INN: PREDNISONE
Other descriptive name: PREDNISONE
ASSISTANCE PUBLIQUE - HOPITAUX DE PARISNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
148 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance
7NCT03864250
(ClinicalTrials.gov)
November 26, 20184/3/2019Tacrolimus Monotherapy for Idiopathic Membranous NephropathyTacrolimus Monotherapy for Idiopathic Membranous Nephropathy: A Randomized, Open, Controlled, Multicenter Clinical TrialTacrolimus;Idiopathic Membranous Nephropathy;Clinical TrialDrug: Tacrolimus;Drug: PrednisoneXinhua Hospital, Shanghai Jiao Tong University School of MedicineNULLRecruiting18 Years80 YearsAll124N/AChina
8NCT03298698
(ClinicalTrials.gov)
August 22, 201824/8/2017Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic SyndromeEfficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Unresponsive to 8 Weeks of High Dose PrednisoneIdiopathic Nephrotic Syndrome;Minimal Change Disease;Focal Segmental GlomerulosclerosisDrug: Rituximab;Drug: PrednisoneRadboud UniversityNULLRecruiting18 YearsN/AAll40Phase 3Netherlands
9NCT03549663
(ClinicalTrials.gov)
July 4, 201810/5/2018Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)Random, Open, Control and Monocentric Clinical Research on Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)Idiopathic Membranous NephropathyDrug: Tacrolimus;Drug: PrednisoneXinhua Hospital, Shanghai Jiao Tong University School of MedicineNULLRecruiting18 Years80 YearsAll108N/AChina
10NCT03466801
(ClinicalTrials.gov)
March 20, 201813/1/2018The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I.The Efficacy of Prednisone Alone and Combination Therapy With Methylprednisolone and Cyclophosphamide in the Treatment of Membranous Nephropathy in Stage I.Idiopathic Membranous NephropathyDrug: Prednisone;Drug: MP and CTXWenhu LiuNULLTerminated18 Years80 YearsAll6N/AChina
11ChiCTR1800014719
2018-02-012018-01-31A retrospective control study of low concentration of tacrolimus combined with prednisone in the treatment of idiopathic focal segmental glomerulosclerosisA retrospective control study of low concentration of tacrolimus combined with prednisone in the treatment of idiopathic focal segmental glomerulosclerosis idiopathic focal segmental glomerulosclerosistacrolimus group:nothing;prednisone group:nothing;the First Affiliated Hospital of Third Military Medical UniversityNULLRecruitingBothtacrolimus group:24;prednisone group:17;China
12ChiCTR1900027627
2017-12-012019-11-22Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathyEfficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy f PLA2R-associated primary membranous nephropathyexperimental group:LEF combined with prednisone;control group:yclophosphamide (CTX) combined with prednisone;Department of Nephrology, The First Affiliated Hospital of Bengbu Medical CollegeNULLCompletedBothexperimental group:30;control group:30;Phase 4China
13NCT02921789
(ClinicalTrials.gov)
May 22, 201730/9/2016Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsA Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsKidney Transplantation;Primary Focal Segmental Glomerulosclerosis (FSGS)Drug: Bleselumab;Drug: Basiliximab;Drug: Mycophenolate Mofetil (MMF);Drug: Tacrolimus Capsules;Drug: Methylprednisone;Drug: PrednisoneAstellas Pharma Global Development, Inc.Kyowa Kirin Co., Ltd.Completed18 YearsN/AAll67Phase 2United States;Canada
14ChiCTR-TQR-12002602
2009-10-092012-10-16The Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of Cholesterol and Bilirubin in the Patients with Minimal Change NephropathyThe Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of Cholesterol and Bilirubin in the Patients with Minimal Change Nephropathy Minimal change nephrotic syndrome in childrenTreatment:prednisone 1~2 mg/kg/day+Fluvastatin Sodium Capsule;Control:prednisone 1~2 mg/kg/day;Treatment center of kidney disease, 281th hospital of PLANULLCompleted412BothTreatment:30;Control:30;I (Phase 1 study)China
15NCT01197040
(ClinicalTrials.gov)
October 20097/9/2010Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic SyndromeLow Steroid Dose Combined With Mycophenolic Acid (Myfortic) Compared With High Dose Steroid for Minimal Change Nephrotic SyndromeNephrotic SyndromeDrug: Prednisone;Drug: acid mycophenolic (Myfortic)Assistance Publique - Hôpitaux de ParisNovartisCompleted18 YearsN/AAll117Phase 3France
16NCT00956059
(ClinicalTrials.gov)
September 200910/8/2009Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental GlomerulosclerosisTherapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental GlomerulosclerosisFocal Segmental GlomerulosclerosisDrug: prednisone, FK506, MMF;Drug: prednisoneXi’an Jiaotong University College of MedicineNULLNot yet recruiting16 Years70 YearsBoth40N/AChina
17NCT00801463
(ClinicalTrials.gov)
January 20092/12/2008Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental GlomerulosclerosisPrednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental GlomerulosclerosisProteinuria;Focal Segmental GlomerulosclerosisDrug: tripterygium wilfordii (TW)Nanjing University School of MedicineNULLCompleted18 Years60 YearsBoth67N/AChina
18EUCTR2007-005410-39-ES
(EUCTR)
11/06/200808/04/2008Estudio piloto aleatorizado comparativo de tacrolimus vs ciclofosfamida-prednisona en la nefropatía membranosa idiopática” - MEMTACEstudio piloto aleatorizado comparativo de tacrolimus vs ciclofosfamida-prednisona en la nefropatía membranosa idiopática” - MEMTAC La nefropatía membranosa idiopática (NMI) es una enfermedad caracterizada histopatológicamente por un engrosamiento uniforme de la pared de los capilares glomerulares, debido al depósito de complejos inmunes a lo largo del espacio subepitelial, en ausencia de inflamación o cambios proliferativos en el resto del glomérulo. El origen exacto de este trastorno se desconoce sin embargo se sabe que la NMI es una causa frecuente de síndrome nefrótico (SN) del adulto.
MedDRA version: 9.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy
Trade Name: Advagraf 0,5mg
INN or Proposed INN: tacrolimus
Trade Name: Genoxal
INN or Proposed INN: ciclofosfamida
Trade Name: Dacortín 2,5mg
INN or Proposed INN: prednisona
Trade Name: Advagraf 1mg
INN or Proposed INN: tacrolimus
Trade Name: Advagraf 5mg
INN or Proposed INN: tacrolimus
Trade Name: Dacortín 5mg
INN or Proposed INN: prednisona
Trade Name: Dacortín 30mg
INN or Proposed INN: prednisona
Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Spain
19ChiCTR-TRC-10001024
2008-01-012010-09-14Tacrolimus versus Cyclophosphamide for Therapy in steroid-resistant and steroid-dependent primary focal segmental glomerulosclerosisTacrolimus versus Cyclophosphamide for Therapy in steroid-resistant and steroid-dependent primary focal segmental glomerulosclerosis primary focal segmental glomerulosclerosisgroup A:intravenous CTX 0.5-0.75g/m2 Monthly+Oral prednisone (Prednisolone) 0.8mg/kg.d ;group B:Oral FK506 FK506 0.1mg/kg.d+prednisone (Prednisolone) 0.5mg/kg.d ;Shanghai Jiaotong University Affiliated Ruijin HospitalNULLCompleted1875Bothgroup A:30;group B:30;China
20NCT00362531
(ClinicalTrials.gov)
November 20049/8/2006Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic SyndromePhase 3 Study of Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic SyndromeIdiopathic Membranous Nephropathy;Nephrotic SyndromeDrug: tacrolimus combined with prednisonePeking UniversityNULLCompleted18 Years70 YearsBothPhase 2/Phase 3NULL
21NCT00135967
(ClinicalTrials.gov)
May 200225/8/2005Mycophenolate Mofetil in Membranous NephropathyTreatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot StudyGlomerulonephritis, MembranousDrug: mycophenolate mofetil orally 1000 mg twice a day (BID);Drug: prednisone 0,5 mg/kg orally on alternate days;Drug: intravenous (i.v.) methylprednisolone 1000 mg, total 9Radboud UniversityHoffmann-La RocheCompleted18 Years75 YearsBoth30Phase 2/Phase 3Netherlands